Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor

被引:109
作者
Breitenbuecher, Frank [1 ,2 ]
Schnittger, Susanne [3 ]
Grundler, Rebekka [4 ]
Markova, Boyka [1 ]
Carius, Birgit [1 ]
Brecht, Alexandra [1 ]
Duyster, Justus [4 ]
Haferlach, Torsten [3 ]
Huber, Christoph [1 ]
Fischer, Thomas [1 ]
机构
[1] Johannes Gutenberg Univ Mainz, Dept Med 3, D-55101 Mainz, Germany
[2] Univ Hosp Essen, W German Canc Ctr, Dept Med Canc Res, Essen, Germany
[3] MLL Munich Leukemia Lab, Munich, Germany
[4] Tech Univ Munich, Munich, Germany
关键词
ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; HUMAN BONE-MARROW; CONSTITUTIVE ACTIVATION; CELL-LINES; TRANSFORMATION; GENE; PROLIFERATION; INHIBITOR; PROGNOSIS;
D O I
10.1182/blood-2007-11-125476
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In acute myeloid leukemia (AML), internal tandem duplications (ITDs) of the juxtamembrane (JM) of FLT3 have been shown to play a crucial role in driving proliferation and survival of the leukemic clone. Here, we report the identification of FLT3_ITD mutations located in non-JM domains of the FLT3-receptor. This novel type of FLT3_ITD mutation was found in 216 of 753 (28.7%) of unselected FLT3_ITD-positive AML cases. An FLT3 receptor harbouring a prototypic non-JM ITD (FLT3_ITD627E) mediated constitutive phosphorylation of FLT3 and of STAT5, suggesting that non-JM ITDs confer constitutive activation of the receptor. FLT3_ITD627E induced transformation of hematopoietic 32D cells and led to a lethal myeloproliferative disease in a syngeneic mouse model. Our results indicate that a significant proportion of activating FLT3_ITD mutations is not confined to the JM domain of FLT3. Further studies are warranted to define the biologic and clinical characteristics of non-JM ITDs. (Blood. 2009; 113: 4074-4077)
引用
收藏
页码:4074 / 4077
页数:4
相关论文
共 21 条
[1]   Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia [J].
Abu-Duhier, FM ;
Goodeve, AC ;
Wilson, GA ;
Care, RS ;
Peake, IR ;
Reilly, JT .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (04) :983-988
[2]   Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myelold transformation [J].
Brandts, CH ;
Sargin, B ;
Rode, M ;
Biermann, C ;
Lindtner, B ;
Schwäble, J ;
Buerger, H ;
Müller-Tidow, C ;
Choudhary, C ;
McMahon, M ;
Berdel, WE ;
Serve, H .
CANCER RESEARCH, 2005, 65 (21) :9643-9650
[3]   Flt3high and Flt3low CD34+ progenitor cells isolated from human bone marrow are functionally distinct [J].
Götze, KS ;
Ramírez, M ;
Tabor, K ;
Small, D ;
Matthews, W ;
Civin, CI .
BLOOD, 1998, 91 (06) :1947-1958
[4]   The structural basis for autoinhibition of FLT3 by the juxtamembrane domain [J].
Griffith, J ;
Black, J ;
Faerman, C ;
Swenson, L ;
Wynn, M ;
Lu, F ;
Lippke, J ;
Saxena, K .
MOLECULAR CELL, 2004, 13 (02) :169-178
[5]   Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines [J].
Hayakawa, F ;
Towatari, M ;
Kiyoi, H ;
Tanimoto, M ;
Kitamura, T ;
Saito, H ;
Naoe, T .
ONCOGENE, 2000, 19 (05) :624-631
[6]   Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain [J].
Heidel, F ;
Solem, FK ;
Breitenbuecher, F ;
Lipka, DB ;
Kasper, S ;
Thiede, MH ;
Brandts, C ;
Serve, H ;
Roesel, J ;
Giles, F ;
Feldman, E ;
Ehninger, G ;
Schiller, GJ ;
Nimer, S ;
Stone, RM ;
Wang, YF ;
Kindler, T ;
Cohen, PS ;
Huber, C ;
Fischer, T .
BLOOD, 2006, 107 (01) :293-300
[7]   FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model [J].
Kelly, LM ;
Liu, Q ;
Kutok, JL ;
Williams, IR ;
Boulton, CL ;
Gilliland, DG .
BLOOD, 2002, 99 (01) :310-318
[8]   Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML) [J].
Kindler, T ;
Breitenbuecher, F ;
Kasper, S ;
Estey, E ;
Giles, F ;
Feldman, E ;
Ehninger, G ;
Schiller, G ;
Klimek, V ;
Nimer, SD ;
Gratwohl, A ;
Choudhary, CR ;
Mueller-Tidow, C ;
Serve, H ;
Gschaidmeier, H ;
Cohen, PS ;
Huber, C ;
Fischer, T .
BLOOD, 2005, 105 (01) :335-340
[9]   Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia [J].
Kindler, T ;
Breitenbuecher, F ;
Marx, A ;
Beck, J ;
Hess, G ;
Weinkauf, B ;
Duyster, J ;
Peschel, C ;
Kirkpatrick, CJ ;
Theobald, M ;
Gschaidmeier, H ;
Huber, C ;
Fischer, T .
BLOOD, 2004, 103 (10) :3644-3654
[10]   A RECEPTOR TYROSINE KINASE SPECIFIC TO HEMATOPOIETIC STEM AND PROGENITOR CELL-ENRICHED POPULATIONS [J].
MATTHEWS, W ;
JORDAN, CT ;
WIEGAND, GW ;
PARDOLL, D ;
LEMISCHKA, IR .
CELL, 1991, 65 (07) :1143-1152